According to the Daewoo Securities' report of 20 March, the annual sales of Dong-A's 'Zydena'(an erectile dysfunction treatment drug) have been on the continuous increase and Dong-A is in the process of new drug production.
The Dong-A's financial report issued in February said that Dong-A showed the higher growth rate of 41.3 % compared with the same period of 2008, thanks to its new drugs and generic products. And the sum of sales of 'Stillen'(an gastric reflux disease treatment drug) was 6.2 billion won in February, up 28.8 % compared with the same month of 2008.
In the Korean market, one of the Asian top pharmaceutical markets, Dong-A's marketshare is expected to go up to 12 % (almost 15 trillion won) in 2009.
The Daewoo Securities' report said that Dong-A would be the 20th pharmaceutical company in Asia within 2012. <헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지